Opinion|Videos|February 6, 2025
Obe-Cel and MRD Outcomes: Insights and Comparisons
Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition (ASH 2024) align with clinical practice, as well as the key findings from the FELIX trial, including minimal residual disease (MRD) outcomes and comparisons with the ZUMA-3 trial for obecabtagene autoleucel (obe-cel) in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. O’Dwyer to Dr. Logan: There’s been a lot of real-world outcomes data with brexu-cel. Can you share some ASH 2024 data updates from CIBMTR and whether these data reflect what you have observed in your day-to-day clinical practice?
- Resource links:
ASH 2024 poster 5092, Wudhikarn K et al, brexu-cel CIMBTR registry updates , or see Appendix 2. - Dr. O’Dwyer to Dr. Molina: One of the biggest updates in ALL is the recent FDA approval of obe-cel. Can you review the FELIX trial, including study design and ASH 2024 updates on MRD outcomes? How is this trial similar and different than ZUMA-3?
Advertisement
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The FDA approved atezolizumab plus chemotherapy for the adjuvant treatment of stage III mismatch repair–deficient colon cancer.
The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.
MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC
5